[go: up one dir, main page]

EP3204075B1 - Dispositif d'injection de médicament avec mécanisme pour faire reculer la tige de piston en changeant la cartouche - Google Patents

Dispositif d'injection de médicament avec mécanisme pour faire reculer la tige de piston en changeant la cartouche Download PDF

Info

Publication number
EP3204075B1
EP3204075B1 EP15777963.8A EP15777963A EP3204075B1 EP 3204075 B1 EP3204075 B1 EP 3204075B1 EP 15777963 A EP15777963 A EP 15777963A EP 3204075 B1 EP3204075 B1 EP 3204075B1
Authority
EP
European Patent Office
Prior art keywords
dose
housing
dose setting
setting element
drug delivery
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP15777963.8A
Other languages
German (de)
English (en)
Other versions
EP3204075A1 (fr
Inventor
Zoë Georgina EARDLEY
Paul Richard Draper
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi SA filed Critical Sanofi SA
Publication of EP3204075A1 publication Critical patent/EP3204075A1/fr
Application granted granted Critical
Publication of EP3204075B1 publication Critical patent/EP3204075B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/24—Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
    • A61M5/31533—Dosing mechanisms, i.e. setting a dose
    • A61M5/31535—Means improving security or handling thereof, e.g. blocking means, means preventing insufficient dosing, means allowing correction of overset dose
    • A61M5/31541—Means preventing setting of a dose beyond the amount remaining in the cartridge
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
    • A61M5/31533—Dosing mechanisms, i.e. setting a dose
    • A61M5/31535—Means improving security or handling thereof, e.g. blocking means, means preventing insufficient dosing, means allowing correction of overset dose
    • A61M5/31543—Means improving security or handling thereof, e.g. blocking means, means preventing insufficient dosing, means allowing correction of overset dose piston rod reset means, i.e. means for causing or facilitating retraction of piston rod to its starting position during cartridge change
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
    • A61M5/31533—Dosing mechanisms, i.e. setting a dose
    • A61M5/31545—Setting modes for dosing
    • A61M5/31548—Mechanically operated dose setting member
    • A61M5/3155—Mechanically operated dose setting member by rotational movement of dose setting member, e.g. during setting or filling of a syringe
    • A61M5/31553—Mechanically operated dose setting member by rotational movement of dose setting member, e.g. during setting or filling of a syringe without axial movement of dose setting member
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
    • A61M5/31565—Administration mechanisms, i.e. constructional features, modes of administering a dose
    • A61M5/31576—Constructional features or modes of drive mechanisms for piston rods
    • A61M5/31583—Constructional features or modes of drive mechanisms for piston rods based on rotational translation, i.e. movement of piston rod is caused by relative rotation between the user activated actuator and the piston rod
    • A61M5/31585—Constructional features or modes of drive mechanisms for piston rods based on rotational translation, i.e. movement of piston rod is caused by relative rotation between the user activated actuator and the piston rod performed by axially moving actuator, e.g. an injection button
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
    • A61M5/31565—Administration mechanisms, i.e. constructional features, modes of administering a dose
    • A61M5/3159—Dose expelling manners
    • A61M5/31593—Multi-dose, i.e. individually set dose repeatedly administered from the same medicament reservoir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
    • A61M2005/2006—Having specific accessories
    • A61M2005/202—Having specific accessories cocking means, e.g. to bias the main drive spring of an injector
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/24—Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic
    • A61M2005/2403—Ampoule inserted into the ampoule holder
    • A61M2005/2407—Ampoule inserted into the ampoule holder from the rear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/24—Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic
    • A61M2005/2477—Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic comprising means to reduce play of ampoule within ampoule holder, e.g. springs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/24—Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic
    • A61M2005/2485—Ampoule holder connected to rest of syringe
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M2005/3125—Details specific display means, e.g. to indicate dose setting
    • A61M2005/3126—Specific display means related to dosing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
    • A61M5/31533—Dosing mechanisms, i.e. setting a dose
    • A61M5/31535—Means improving security or handling thereof, e.g. blocking means, means preventing insufficient dosing, means allowing correction of overset dose
    • A61M5/31536—Blocking means to immobilize a selected dose, e.g. to administer equal doses
    • A61M2005/3154—Blocking means to immobilize a selected dose, e.g. to administer equal doses limiting maximum permissible dose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/58—Means for facilitating use, e.g. by people with impaired vision
    • A61M2205/581—Means for facilitating use, e.g. by people with impaired vision by audible feedback
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/58—Means for facilitating use, e.g. by people with impaired vision
    • A61M2205/582—Means for facilitating use, e.g. by people with impaired vision by tactile feedback
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/58—Means for facilitating use, e.g. by people with impaired vision
    • A61M2205/583—Means for facilitating use, e.g. by people with impaired vision by visual feedback
    • A61M2205/584—Means for facilitating use, e.g. by people with impaired vision by visual feedback having a color code

Definitions

  • the present invention is generally directed to a drug delivery device for selecting and dispensing a number of user variable doses of a medicament, and a method of assembling same.
  • Pen type drug delivery devices have application where regular injection by persons without formal medical training occurs. This may be increasingly common among patients having diabetes where self-treatment enables such patients to conduct effective management of their disease.
  • a drug delivery device allows a user to individually select and dispense a number of user variable doses of a medicament.
  • the present invention is not directed to so called fixed dose devices which only allow dispensing of a predefined dose without the possibility to increase or decrease the set dose.
  • resettable devices i.e., reusable
  • non-resettable i.e., disposable
  • disposable pen delivery devices are supplied as self-contained devices.
  • Such self-contained devices do not have removable pre-filled cartridges. Rather, the pre-filled cartridges may not be removed and replaced from these devices without subverting the device itself. Consequently, such disposable devices need not have a resettable dose setting mechanism.
  • the present invention is directed to reusable devices which allow resetting of the device and a replacement of a cartridge. Resetting of the device typically involves moving a piston rod or lead screw from an extended (distal) position, i.e. a position after dose dispensing, into a more retracted (proximal) position.
  • a cartridge typically includes a reservoir that is filled with a medication (e.g., insulin), a movable rubber type bung or stopper located at one end of the cartridge reservoir, and a top having a pierceable rubber seal located at the other, often necked-down, end.
  • a crimped annular metal band is typically used to hold the rubber seal in place.
  • cartridge housing may be typically made of plastic
  • cartridge reservoirs have historically been made of glass.
  • the needle assembly is typically a replaceable double-ended needle assembly. Before an injection, a replaceable double-ended needle assembly is attached to one end of the cartridge assembly, a dose is set, and then the set dose is administered. Such removable needle assemblies may be threaded onto, or pushed (i.e., snapped) onto the pierceable seal end of the cartridge assembly.
  • the dosing section or dose setting mechanism is typically the portion of the pen device that is used to set (select) a dose.
  • a spindle or piston rod contained within the dose setting mechanism presses against the bung or stopper of the cartridge. This force causes the medication contained within the cartridge to be injected through an attached needle assembly. After an injection, as generally recommended by most drug delivery device and/or needle assembly manufacturers and suppliers, the needle assembly is removed and discarded.
  • a further differentiation of drug delivery device types refers to the drive mechanism: There are devices which are manually driven, e.g. by a user applying a force to an injection button, devices which are driven by a spring or the like and devices which combine these two concepts, i.e. spring assisted devices which still require a user to exert an injection force.
  • the spring-type devices involve springs which are preloaded and springs which are loaded by the user during dose selecting. Some stored-energy devices use a combination of spring preload and additional energy provided by the user, for example during dose setting.
  • Manually driven reusable drug delivery devices are known e.g. from WO 2014/033195 A1 and EP 2 274 030 B1 . These devices comprise a last dose mechanism preventing setting of a dose which exceeds the amount of medicament remaining in the cartridge. Replacing a cartridge allows resetting of this last dose mechanism by pushing the piston rod in a direction opposite to the dispensing direction.
  • EP 1 819 382 B1 discloses a spring driven drug delivery device with a housing, a dose setting element rotatable relative to the housing during dose setting and dose dispensing between a minimum dose position and a maximum dose position, a drive member coupled to the dose setting member via a ratchet, and a piston rod threaded to a housing insert and rotationally constrained to the drive member. Resetting of the device is mentioned in this document differing from the above definition as the process of reducing a set dose. Replacing a cartridge and resetting e.g. the piston rod is not disclosed in EP 1 819 382 B1 .
  • Resettable drug delivery devices allowing replacing an empty cartridge are known for example from US 5,104,380 , US 2012/0209212 A1 , US 2012/0136315 A1 and US 2009/0247960 A1 .
  • Resetting is effected in the device of US 5,104,380 by disengaging the threaded interface between a driver and the piston rod, thus allowing to push back the piston rod.
  • resetting is effected by axially displacing the piston rod a small distance which decouples two parts of the driver from each other.
  • a drug delivery device according to the present invention is suitable for selecting and dispensing a number of user variable doses of a medicament.
  • the device typically comprises a housing, a dose setting element, a drive member coupled to the dose setting member via a clutch and a piston rod coupled to the housing and to the drive member.
  • the dose setting member is rotatable relative to the housing during dose setting, i.e. increasing or decreasing the dose, and dose dispensing between a minimum dose position and a maximum dose position.
  • the drive member is rotationally coupled to the dose setting member via a slipping clutch during dose setting and rotationally constrained to the dose setting member during dose dispensing.
  • the present invention is based on the idea of providing a cartridge holder removably attached to the housing and a reset element.
  • the reset element is axial-ly constrained to the dose setting element.
  • the device may comprise at least one spring acting on the reset element, such that, if the cartridge holder is detached from the housing, the reset element is axially moved relative to the housing into a position in which the drive member is allowed to rotate relative to the housing.
  • the reset element is axially moved relative to the housing into a position in which the dose setting element is rotationally constrained to the housing.
  • detachment of the cartridge holder from the housing allows an axial movement of the reset element and, the dose setting element into a resetting position, in which the drive member may be rotated relative to the housing and relative to the dose setting member.
  • the piston rod is coupled to the housing and to the drive member, e.g.
  • resetting of the piston rod requires free rotation of the drive member.
  • resetting of the drug delivery device is performed simply by pushing back the piston rod or lead screw after removal of the cartridge holder.
  • the cartridge holder preferably moves the reset element and the dose setting element against the bias of the at least one spring into a position in which the dose setting element is rotatable relative to the housing.
  • attachment of the cartridge holder locks the device in a dose setting and dose dispensing mode allowing dose setting and dose dispensing which requires rotation of the dose setting element relative to the housing.
  • the reset element is permanently rotationally constrained to the housing. This allows the reset element to rotationally lock or unlock (constrain or unconstrain) component parts to the housing by engaging or disengaging the reset element with component parts.
  • the axial movement of the reset element between the resetting mode and the dose setting and dose dispensing mode may be used to couple or decouple component parts to or from the housing.
  • the drive member is axially movable relative to the housing between a dose setting position in which the drive member is rotationally constrained to the housing via the reset element and a dose dispensing position in which the drive member is rotatable relative to the reset element and the housing.
  • the axial position of the drive member determines whether the device is in a dose setting mode allowing a user to increase or decrease a dose by rotation of the dose setting member without dispensing medicament or in a dose dispensing mode allowing a user to dispense a set dose by rotation of the dose setting element and the drive member.
  • the at least one spring biases the drive member into its dose setting position.
  • the clutch between the dose setting element and the drive member is a slipping clutch with first clutch teeth on the drive member and second clutch teeth on a clutch plate, which is rotationally constrained to the dose setting element during dose setting and dose dispensing.
  • first and/or second clutch teeth may each be distributed as a ring of teeth, preferably facing in the axial direction.
  • the clutch features and the corresponding clutch features may each comprise a series of teeth, preferably saw-teeth, which are allowed to slip over each other if not pressed against each other too firmly.
  • the clutch features may be overhauled against the axial bias of a clutch spring by allowing the sleeve and/or the clutch element to translate axially against the force of the clutch spring. This may result in an oscillating axial movement of the sleeve and/or the clutch element due to continued disengagement and following re-engagement into the next detented position. An audible click may be generated by this re-engagement, and tactile feedback may be given by the change in torque input required.
  • the at least one spring may bias the drive member into abutment with the clutch plate. If the cartridge holder is detached from the housing, the at least one spring may bias the dose setting element into an axial position relative to the clutch plate in which the clutch plate and the dose setting element are rotationally de-coupled. This allows rotation of the drive member relative to the dose setting element without overcoming the slipping clutch.
  • the clutch between the drive member and the dose setting element is a slipping clutch which allows relative rotation between the drive member and the dose setting element in both directions during dose setting for increasing or decreasing a set dose.
  • the clutch teeth may be designed to provide a different resistance for overcoming the clutch depending on the direction of the relative rotation.
  • the ramp angle may be shallower resulting in a lower resistance in the dose increasing direction and steeper resulting in a higher resistance in the dose decreasing direction.
  • the housing may comprise an inwardly protruding wall or web with a central opening and at least one further opening with one of the cartridge holder and the reset element comprising at least one axially extending finger or the like protrusion extending through the further opening.
  • the inwardly protruding wall or web comprises an inner thread wherein the piston rod is rotationally constrained to the drive member and comprises an outer thread engaging the inner thread.
  • the drug delivery device may further comprise at least one cartridge holder spring axially interposed between the cartridge holder and the inwardly protruding wall or web. This additional spring may compensate length tolerances of the cartridge and further bring the cartridge in a defined distal position.
  • the drug delivery device is a spring driven device.
  • a drive spring preferably a torsion spring
  • Providing a resilient drive member, such as a torsion spring, generating the force or torque required for dose dispensing reduces the user applied forces for dose dispensing. This is especially helpful for users with impaired dexterity.
  • the dial extension of the known manually driven devices which is a result of the required dispensing stroke, may be omitted by providing the resilient member because merely a small triggering stroke may be necessary for releasing the resilient member.
  • the drive spring may be pre-charged, at least partly, and/or may be charged by a user during dose setting.
  • the drug delivery device further comprises a gauge element radially interposed between the housing and the dose setting element.
  • the gauge element is axially movable relative to the housing and in threaded engagement with the dose setting element.
  • the housing may comprise at least one aperture and the gauge element may comprise at least one aperture. If the dose setting element is a number sleeve which comprises markings on its outer surface, at least one of the markings is visible through the aperture in the gauge element and the aperture in the housing during dose setting and dose dispensing.
  • the term aperture may include a simple opening in the housing or gauge element or a transparent window or lens.
  • a window in the housing may be incorporated using a 'twin-shot' moulding technology. For example, the housing is moulded during a 'first shot' in a translucent material, and the outer cover of the housing is moulded during a 'second shot' in an opaque material.
  • the gauge element may be axially guided within the housing such that rotation of the dose setting element causes an axial displacement of the gauge element.
  • the position of the gauge element may thus be used to identify the actually set and/or dispensed dose. Different colours of sections of the gauge member may facilitate identifying the set and/or dispensed dose without reading numbers, symbols or the like on a display.
  • rotation of the dose setting element causes an axial displacement of the gauge element relative to the dose setting element and relative to the housing.
  • the gauge element may have the form of a shield or strip extending in the longitudinal direction of the device.
  • the gauge element may be a sleeve.
  • the dose setting element is marked with a sequence of numbers or symbols arranged on a helical path. With the dose setting element located radially inwards of the gauge element, this allows that at least one of the numbers or symbols on the dose setting element is visible through the aperture or window.
  • the gauge element may be used to shield or cover a portion of the dose setting element and to allow viewing onto only a limited portion of the dose setting element. This function may be in addition to the gauge element itself being suitable for identifying or indicating the actually set and/or dispensed dose.
  • the concept of the gauge element and the dose setting element is applicable for various types of devices with or without a drive spring.
  • the dose setting element during dose setting, is adapted to undergo a mere rotational movement within the housing and relative to the housing. In other words, the dose setting element does not perform a translational movement during dose setting. This avoids that the dose setting element is wound out of the housing or that the housing has to be lengthened to cover the dose setting element within the housing.
  • the relative movements of the gauge element and the dose setting element may further be used to define the minimum dose position and the maximum dose position.
  • the minimum settable dose is zero (0 IU of insulin formulation), such that the limiter stops the device at the end of dose dispensing.
  • the maximum settable dose for example 60, 80 or 120 IU of insulin formulation, may be limited to reduce the risk of overdosage and to avoid the additional spring torque needed for dispensing very high doses, while still being suitable for a wide range of patients needing different dose sizes.
  • the limits for the minimum dose and the maximum dose are provided by hard stop features.
  • the gauge element comprises a minimum dose rotational stop and a maximum dose rotational stop and the dose setting element comprises a minimum dose rotational counter stop and a maximum dose rotational counter stop. Abutment of the respective stop and counter stop blocks further relative movement between the gauge element and the dose setting element. As the dose indicator rotates relative to the gauge element during dose setting and during dose dispensing, these two components are suitable to form a reliable and robust limiter mechanism.
  • the device may further comprise a dispensing button or trigger.
  • the button is preferably a user operable element located proximally of the drive sleeve and the clutch element. When used in a drug delivery device, the button may extend from the proximal end of the device and, preferably, does not change its axial position during dose setting.
  • the button is preferably coupled to a user operable dose selector and may be releasably coupled to a number sleeve component and/or a stationary housing component.
  • the button may be part of a dose setting arrangement or may be the dose setting member.
  • the button may be a multi-functional element having in addition to the above features e.g. a clicker feature.
  • the stationary housing component is a fixed basis for relative movements of the axially movable (drive) sleeve, the clutch element and the button. It may be part of a multi-component housing or may be the only housing component of a drug delivery device.
  • the housing component may be a multi-functional element having in addition to the above features e.g. a clicker feature and/or an interface to the piston rod.
  • the drug delivery device comprises a last dose protection mechanism for preventing the setting of a dose, which exceeds the amount of liquid left in a cartridge. This has the advantage that the user knows how much will be delivered before starting the dose delivery. It also ensures that dose delivery stops in a controlled manner without the bung entering the neck portion of the cartridge where the diameter is smaller which may result in an underdose.
  • the last dose protection mechanism comprises a nut member interposed between the drive member and the dose setting element (number sleeve) or any other component which rotates during dose setting and dose dispensing.
  • the dose setting element rotates during dose setting and during dose dispensing, whereas the drive member only rotates during dose dispensing together with the dose setting element.
  • the nut member will only move axially during dose setting and will remain stationary with respect to these components during dose dispensing.
  • the nut member is threaded to the drive member and splined to the dose setting member.
  • the nut member may be threaded to the dose setting member and may be splined to the drive member.
  • the nut member may be a full nut or a part thereof, e.g. a half nut.
  • the injection device may comprise at least one clicker mechanism for generating a tactile and/or audible feedback.
  • a feedback may be generated during dose setting (increasing and/or decreasing a dose), dose dispensing and/or at the end of dose dispensing.
  • the drug delivery device may comprise a cartridge containing a medicament.
  • medicament means a pharmaceutical formulation containing at least one pharmaceutically active compound, wherein in one embodiment the pharmaceutically active compound has a molecular weight up to 1500 Da and/or is a peptide, a proteine, a polysaccharide, a vaccine, a DNA, a RNA, an enzyme, an antibody or a fragment thereof, a hormone or an oligonucleotide, or a mixture of the above-mentioned pharmaceutically active compound, wherein in a further embodiment the pharmaceutically active compound is useful for the treatment and/or prophylaxis of diabetes mellitus or complications associated with diabetes mellitus such as diabetic retinopathy, thromboembolism disorders such as deep vein or pulmonary thromboembolism, acute coronary syndrome (ACS), angina, myocardial infarction, cancer, macular degeneration, inflammation, hay fever, atherosclerosis and/or rheumato
  • Insulin analogues are for example Gly(A21), Arg(B31), Arg(B32) human insulin; Lys(B3), Glu(B29) human insulin; Lys(B28), Pro(B29) human insulin; Asp(B28) human insulin; human insulin, wherein proline in position B28 is replaced by Asp, Lys, Leu, Val or Ala and wherein in position B29 Lys may be replaced by Pro; Ala(B26) human insulin; Des(B28-B30) human insulin; Des(B27) human insulin and Des(B30) human insulin.
  • Insulin derivates are for example B29-N-myristoyl-des(B30) human insulin; B29-N-palmitoyl-des(B30) human insulin; B29-N-myristoyl human insulin; B29-N-palmitoyl human insulin; B28-N-myristoyl LysB28ProB29 human insulin; B28-N-palmitoyl-LysB28ProB29 human insulin; B30-N-myristoyl-ThrB29LysB30 human insulin; B30-N-palmitoyl- ThrB29LysB30 human insulin; B29-N-(N-palmitoyl-Y-glutamyl)-des(B30) human insulin; B29-N-(N-lithocholyl-Y-glutamyl)-des(B30) human insulin; B29-N-( ⁇ -carboxyheptadecanoyl)-des(B30) human insulin and B29-N-( ⁇ -carbox
  • Exendin-4 for example means Exendin-4(1-39), a peptide of the sequence H-His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-lle-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2.
  • Exendin-4 derivatives are for example selected from the following list of compounds:
  • Hormones are for example hypophysis hormones or hypothalamus hormones or regulatory active peptides and their antagonists as listed in Rote Liste, ed. 2008, Chapter 50 , such as Gonadotropine (Follitropin, Lutropin, Choriongonadotropin, Menotropin), Somatropine (Somatropin), Desmopressin, Terlipressin, Gonadorelin, Triptorelin, Leuprorelin, Buserelin, Nafarelin, Goserelin.
  • Gonadotropine Follitropin, Lutropin, Choriongonadotropin, Menotropin
  • Somatropine Somatropin
  • Desmopressin Terlipressin
  • Gonadorelin Triptorelin
  • Leuprorelin Buserelin
  • Nafarelin Goserelin.
  • a polysaccharide is for example a glucosaminoglycane, a hyaluronic acid, a heparin, a low molecular weight heparin or an ultra low molecular weight heparin or a derivative thereof, or a sulphated, e.g. a poly-sulphated form of the above-mentioned polysaccharides, and/or a pharmaceutically acceptable salt thereof.
  • An example of a pharmaceutically acceptable salt of a poly-sulphated low molecular weight heparin is enoxaparin sodium.
  • Antibodies are globular plasma proteins (-150 kDa) that are also known as immunoglobulins which share a basic structure. As they have sugar chains added to amino acid residues, they are glycoproteins.
  • the basic functional unit of each antibody is an immunoglobulin (Ig) monomer (containing only one Ig unit); secreted antibodies can also be dimeric with two Ig units as with IgA, tetrameric with four Ig units like teleost fish IgM, or pentameric with five Ig units, like mammalian IgM.
  • Ig immunoglobulin
  • the Ig monomer is a "Y"-shaped molecule that consists of four polypeptide chains; two identical heavy chains and two identical light chains connected by disulfide bonds between cysteine residues. Each heavy chain is about 440 amino acids long; each light chain is about 220 amino acids long. Heavy and light chains each contain intrachain disulfide bonds which stabilize their folding. Each chain is composed of structural domains called Ig domains. These domains contain about 70-110 amino acids and are classified into different categories (for example, variable or V, and constant or C) according to their size and function. They have a characteristic immunoglobulin fold in which two ⁇ sheets create a "sandwich" shape, held together by interactions between conserved cysteines and other charged amino acids.
  • Ig heavy chain There are five types of mammalian Ig heavy chain denoted by a, ⁇ , ⁇ , ⁇ , and ⁇ .
  • the type of heavy chain present defines the isotype of antibody; these chains are found in IgA, IgD, IgE, IgG, and IgM antibodies, respectively.
  • Distinct heavy chains differ in size and composition; ⁇ and ⁇ contain approximately 450 amino acids and ⁇ approximately 500 amino acids, while ⁇ and ⁇ have approximately 550 amino acids.
  • Each heavy chain has two regions, the constant region (CH) and the variable region (VH).
  • the constant region is essentially identical in all antibodies of the same isotype, but differs in antibodies of different isotypes.
  • Heavy chains ⁇ , ⁇ and ⁇ have a constant region composed of three tandem Ig domains, and a hinge region for added flexibility; heavy chains ⁇ and ⁇ have a constant region composed of four immunoglobulin domains.
  • the variable region of the heavy chain differs in antibodies produced by different B cells, but is the same for all antibodies produced by a single B cell or B cell clone.
  • the variable region of each heavy chain is approximately 110 amino acids long and is composed of a single Ig domain.
  • a light chain has two successive domains: one constant domain (CL) and one variable domain (VL).
  • CL constant domain
  • VL variable domain
  • the approximate length of a light chain is 211 to 217 amino acids.
  • Each antibody contains two light chains that are always identical; only one type of light chain, ⁇ or ⁇ , is present per antibody in mammals.
  • variable (V) regions are responsible for binding to the antigen, i.e. for its antigen specificity.
  • VL variable light
  • VH variable heavy chain
  • CDRs Complementarity Determining Regions
  • an "antibody fragment” contains at least one antigen binding fragment as defined above, and exhibits essentially the same function and specificity as the complete antibody of which the fragment is derived from.
  • Limited proteolytic digestion with papain cleaves the Ig prototype into three fragments. Two identical amino terminal fragments, each containing one entire L chain and about half an H chain, are the antigen binding fragments (Fab).
  • the Fc contains carbohydrates, complement-binding, and FcR-binding sites.
  • F(ab')2 is divalent for antigen binding.
  • the disulfide bond of F(ab')2 may be cleaved in order to obtain Fab'.
  • the variable regions of the heavy and light chains can be fused together to form a single chain variable fragment (scFv).
  • Pharmaceutically acceptable salts are for example acid addition salts and basic salts.
  • Acid addition salts are e.g. HCI or HBr salts.
  • Basic salts are e.g. salts having a cation selected from alkali or alkaline, e.g. Na+, or K+, or Ca2+, or an ammonium ion N+(R1)(R2)(R3)(R4), wherein R1 to R4 independently of each other mean: hydrogen, an optionally substituted C1-C6-alkyl group, an optionally substituted C2-C6-alkenyl group, an optionally substituted C6-C10-aryl group, or an optionally substituted C6-C10-heteroaryl group.
  • solvates are for example hydrates.
  • FIG. 1 shows a drug delivery device in the form of an injection pen.
  • the device has a distal end (left end in Figure 1 ) and a proximal end (right end in Figure 1 ).
  • the component parts of the drug delivery device are shown in Figure 2 .
  • the drug delivery device comprises a body or housing 10, a cartridge holder 20, a lead screw (piston rod) 30, a drive sleeve 40, a nut 50, a dose setting element which is a dose indicator (number sleeve) 60, a button 70, a dial grip or dose selector 80, a torsion spring 90, a cartridge 100, a gauge element 110, a clutch plate 120, a clutch spring 130, a bearing 140, a reset plate 150 and a cartridge holder spring 160.
  • a needle arrangement (not shown) with a needle hub and a needle cover may be provided as additional components, which can be exchanged as explained above. All components are located concentrically about a common principal axis I of the
  • the housing 10 or body is a generally tubular element having a proximal end with an enlarged diameter.
  • the housing 10 provides location for the liquid medication cartridge 100 and cartridge holder 20, windows 11a, 11b for viewing the dose number on the dose indicator 60 and the gauge element 110, and a feature on its external surface, e.g. a circumferential groove, to axially retain the dose selector 80. It is also possible in another embodiment to have one large window. Then the opaque bridge between windows 11a and 11b is replaced by a transparent area.
  • a flange-like or cylindrical inner wall 12 comprises an inner thread engaging the piston rod 30.
  • the housing 10 further has at least one internal, axially orientated slot or the like for axially guiding the gauge element 110.
  • the distal end is provided with an axially extending strip 13 partly overlapping cartridge holder 20.
  • the Figures depict the housing 10 as a single housing component. However, the housing 10 could comprise two or more housing components which may be permanently attached to each other during assembly of the device.
  • the cartridge holder 20 is located at the distal end of housing 10 and attached thereto in a releasable manner.
  • the cartridge holder may be a transparent or translucent component which is tubular to receive cartridge 100.
  • the distal end of cartridge holder 20 may be provided with means for attaching a needle arrangement.
  • a removable cap (not shown) may be provided to fit over the cartridge holder 20 and may be retained via clip features on the housing 10.
  • the cartridge holder 20 contains the replaceable cartridge 100 and acts to axially align the reset plate 150 spline teeth 151 with the drive sleeve 40 spline teeth 41.
  • the trigger spring 130 forces the reset plate 150 (and dose setting element 60) axially in a distal direction, disengaging the spline teeth 41, 151 between the reset plate 150 and the drive sleeve 40 and the spline teeth between the clutch plate 120 and the dose setting element 60, allowing the device to be reset.
  • the piston rod 30 is rotationally constrained to the drive sleeve 40 via a splined interface. When rotated, the piston rod 30 is forced to move axially relative to the housing 10, through its threaded interface with the housing 10.
  • the drive sleeve 40 extends from the interface 42, 121 with the dose setting element 60 (via the clutch plate 120) down to a splined tooth interface 41, 151 ( Figure 6 ) with the reset plate 150. This provides a rotational constraint to the drive sleeve 40 during dose setting.
  • these spline teeth 41, 151 are disengaged allowing the drive sleeve 40 to rotate under the action of the drive spring 90, dispensing the set dose. Pressing the button 70 also engages an additional spline clutch 43, 61 ( Figure 7a ) between the drive sleeve 40 and dose setting element 60.
  • the last dose nut 50 is located between the dose setting element 60 and the drive sleeve 40. It is rotationally constrained to the dose setting element 60, via a splined interface. It moves along a helical path relative to the drive sleeve 40, via a threaded interface 44, when relative rotation occurs between the dose setting element 60 and drive sleeve 40 (during dialling and resetting only).
  • the dose setting element 60 is constrained, via a clip at its distal end, to the reset plate 150 to allow rotation but not axial translation when in the dialling and dispense conditions.
  • the reset plate 150 and dose setting element 60 move axially in the distal direction, engaging a spline interface 62, 14 between the dose setting element 60 and the housing 10 to prevent rotation during reset ( Figures 12a to 12c ).
  • the dose setting element 60 is marked with a sequence of numbers, which are visible through opening 111 ( Figure 4 ) in the gauge element 110 and the slot-like window 11b in the housing 10, to denote the dialled dose of medicament.
  • the button 70 is splined to the dose setting element 60 when in the dose dialling condition. This spline interface is disconnected when the button 70 is pressed to trigger a dispense.
  • the dose selector 80 is radially constrained to the housing 10 and rotationally constrained to the button 70.
  • the button 70 is rotationally constrained to the housing 10 via a splined engagement.
  • the drive spring 90 is attached at one end to the housing 10 and at the other end to the dose setting element 60.
  • the drive spring 90 is pre-wound upon assembly, such that it applies a torque to the dose setting element 60 when the mechanism is at zero count dialled.
  • the action of rotating the dose selector 80, to set a dose rotates the dose setting element 60 relative to the housing 10, and charges the drive spring 90.
  • the gauge element 110 is constrained to prevent rotation but allow translation relative to the housing 10 via a splined interface.
  • the gauge element 110 has helical features 112 on its inner surface which engage with the helical thread 63 formed in the dose setting element 60 such that rotation of the dose setting element 60 causes axial translation of the gauge element 110.
  • These helical features on the gauge element 110 also create stop abutments against the ends of the helical cut (thread) in the dose setting element 60 to limit the minimum and maximum dose that can be set.
  • the clutch plate 120 is splined to the dose setting element 60 when in the dialling and dispense conditions. On entry to the reset condition the dose setting element 60 moves axially in a distal direction, disconnecting this spline interface with the clutch plate 120.
  • the clutch plate 120 is also coupled to the drive sleeve 40 via a ratchet interface 42, 121 ( Figure 7a ), which occurs on an axial abutment.
  • the ratchet provides a detented position between the dose setting element 60 and drive sleeve 40 corresponding to each dose increment, and engages different ramped tooth angles during clockwise and anti-clockwise relative rotation.
  • the relative axial positions of the drive sleeve 40, clutch plate 120 and button 70 are influenced by the action of the trigger spring 130, which applies a biasing force on the drive sleeve 40 in the proximal direction. In the at rest position, this ensures that splines 71 of the button 70 are engaged with splines 64 of the dose setting element 60 and that the drive sleeve 40 teeth 41 are engaged with teeth 151 of the reset plate 150 ( Figures 8a, 8b ).
  • the bearing 140 is axially constrained to the piston rod 30 and acts on the bung within the liquid medicament cartridge 100.
  • the reset plate 150 is rotationally splined to the housing 10 and biased in a distal direction against the cartridge holder 20 by the trigger spring 130.
  • the reset plate 150 contains spline teeth 151 that prevent rotation of the drive sleeve 40 during dialling of the device, and clips to prevent axial motion of the dose setting element 60 in the dialling and dispense conditions.
  • the reset plate 150 clips into the housing 10 to limit its range of motion in the proximal direction.
  • the cartridge holder spring 160 acts between the housing 10 and the cartridge 100 to bias the cartridge 100 in the distal direction.
  • the dose setting element 60 With the device in the at rest condition as shown in Figure 3 , the dose setting element 60 is positioned against its zero dose abutment with the gauge element 110, and the button 70 is not depressed. Dose marking '0' on the dose setting element 60 is visible through the window 11b of the housing 10 and gauge element 110.
  • the drive spring 90 which has a number of pre-wound turns applied to it during assembly of the device, applies a torque to the dose setting element 60 and is prevented from rotating by the zero dose abutment. It is also possible to "back-wind" the mechanism slightly due to an offset between the zero dose stop and the angular offset of the drive sleeve spline teeth 41. This has the effect of preventing possible weepage when a dose is dialled and the zero dose abutment is disengaged.
  • the user selects a variable dose of liquid medicament by rotating the dose selector 80 clockwise, which generates an identical rotation in the dose setting element 60.
  • Rotation of the dose setting element 60 causes charging of the drive spring 90, increasing the energy stored within it.
  • the gauge element 110 translates axially due to its threaded engagement 63, 112 thereby showing the value of the dialled dose.
  • the gauge element 110 has opaque surfaces (flanges) either side of the window area 111 which cover the numbers printed on the dose setting element 60 adjacent to the dialled dose to ensure only the set dose number is made visible to the user.
  • One specific element of this mechanism is inclusion of a visual feedback feature in addition to the discrete dose number display typical on devices of this type.
  • the distal end of the gauge element 110 creates a sliding scale (although this could be formed using a separate component engaged with the dose setting element 60 on a different helical track if desired) through the small window 11a in the housing 10.
  • the gauge element 110 translates axially, the distance moved proportional to the magnitude of the dose set.
  • This feature gives clear feedback to the user regarding the approximate size of the dose set.
  • the dispense speed of an auto-injector mechanism may be higher than for a manual injector device, so it may not be possible to read the numerical dose display during dispense.
  • the gauge element 110 feature provides feedback to the user during dispense regarding dispense progress without the need to read the dose number itself.
  • the gauge element 110 display may be formed by an opaque sliding element revealing a contrasting coloured component underneath.
  • the concealed component may be printed with coarse (occasional) dose numbers or other indices to provide more precise resolution.
  • the gauge element 110 display simulates a syringe action during dose set and dispense.
  • the drive sleeve 40 is prevented from rotating as the dose is set due to the engagement of its splined teeth 41 with the reset plate 150, and the clutch plate 120 is rotated due to the engagement of its splined teeth 122 with teeth 65 of the dose setting element 60 ( Figures 8a, 8b ). Relative rotation must therefore occur between the clutch plate 120 and drive sleeve 40 via the ratchet interface 121, 42.
  • the user torque required to rotate the dose selector 80 is a sum of the torque required to wind up the drive spring 90, and the torque required to overhaul the ratchet feature.
  • the trigger spring 130 is designed to provide an axial force to the ratchet feature and to bias the clutch plate 120 onto the drive sleeve 40. This axial load acts to maintain the ratchet teeth engagement of the clutch plate 120 and drive sleeve 40.
  • the torque required to overhaul the ratchet in the dose set direction is a function of the axial load applied by the trigger spring 130, the clockwise ramp angle of the ratchet, the friction coefficient between the mating surfaces and the mean radius of the ratchet features.
  • the clutch plate 120 rotates relative to the drive sleeve 40 by 1 ratchet tooth 121, 42. At this point the ratchet teeth re-engage into the next detented position. An audible click is generated by the ratchet re-engagement, and tactile feedback is given by the change in torque input required.
  • Relative rotation of the dose setting element 60 and the drive sleeve 40 causes the last dose nut 50 to travel along its threaded path, towards its last dose abutment on the drive sleeve 40.
  • the torque necessary to overhaul the ratchet 121, 42 in the anti-clockwise direction is a function of the axial load applied by the trigger spring 130, the anti-clockwise ramp angle of the ratchet, the friction coefficient between the mating surfaces and the mean radius of the ratchet features.
  • the torque necessary to overhaul the ratchet must be greater than the torque applied to the dose setting element 60 (and hence clutch plate 120) by the drive spring 90.
  • the ratchet ramp angle is therefore increased in the anti-clockwise direction to ensure this is the case whilst ensuring the dial-up torque is acceptably low.
  • the user may now choose to increase the selected dose by continuing to rotate the dose selector 80 in the clockwise direction.
  • the process of overhauling the ratchet interfaces 121, 42 between the dose setting element 60 and drive sleeve 40 is repeated for each dose increment. Additional energy is stored within the drive spring 90 for each dose increment and audible and tactile feedback is provided for each increment dialled by the re-engagement of the ratchet teeth.
  • the torque required to rotate the dose selector 80 increases as the torque required to wind up the drive spring 90 increases.
  • the torque required to overhaul the ratchet in the anti-clockwise direction must therefore be greater than the torque applied to the dose setting element 60 by the drive spring 90 when the maximum dose has been reached.
  • the dose setting element 60 engages with its maximum dose abutment on the gauge element 110 ( Figures 4 and 5 ). This prevents further rotation of the dose setting element 60, clutch plate 120 and dose selector 80.
  • the last dose nut 50 may contact its last dose abutment with the drive sleeve 40.
  • the abutment prevents further relative rotation between the dose setting element 60 and the drive sleeve 40, and therefore limits the dose that can be selected.
  • the position of the last dose nut 50 is determined by the total relative rotation between the dose setting element 60 and drive sleeve 40, that has accumulated each time the user has set a dose.
  • the user With the mechanism in a state in which a dose has been selected, the user is able to deselect any number of increments from this dose (dose correction). Deselecting or decreasing a dose is achieved by the user rotating the dose selector 80 anti-clockwise.
  • the torque applied to the dose selector 80 by the user is sufficient, when combined with the torque applied by the drive spring 90, to overhaul the ratchet 121, 42 between the clutch plate 120 and drive sleeve 40 in the anti-clockwise direction.
  • anti-clockwise rotation occurs in the dose setting element 60 (via the clutch plate 120), which returns the dose setting element 60 towards the zero dose position, and unwinds the drive spring 90.
  • the relative rotation between the dose setting element 60 and drive sleeve 40 causes the last dose nut 50 to return along its helical path, away from the last dose abutment.
  • the user With the mechanism in a state in which a dose has been selected, the user is able to activate the mechanism to commence delivery of a dose. Delivery of a dose is initiated by the user depressing the button 70 axially.
  • buttons 70 When the button 70 is depressed, splines 64, 71 between the button 70 and dose setting element 60 are disengaged, rotationally disconnecting the button 70 and dose selector 80 from the delivery mechanism. Splines 71 on the button 70 also engage with splines 15 on the housing 10 (so that the dose selector 80 and button 70 do not rotate during dispense - see Figure 8a and 8b ).
  • the button 70 force acts on the drive sleeve 40, via the clutch plate 120, which travels axially and disconnects the splined engagement with the reset plate 150, allowing rotation of the drive sleeve 40.
  • the force on the clutch plate 120 to drive sleeve 40 ratchet is increased by compression of the trigger spring 130, causing these components to spin together rather than overhaul the ratchet 121, 42, driven by the drive spring 90 via the dose setting element 60.
  • Rotation of the drive sleeve 40 causes the piston rod 30 to rotate due to their splined engagement, and the piston rod 30 then advances due to its threaded engagement to the housing 10.
  • the dose setting element 60 rotation also causes the gauge element 110 to traverse axially back to its zero position whereby the zero dose abutment stops the mechanism.
  • Tactile feedback during dose dispense is provided via a compliant cantilever clicker arm 72 integrated into the button 70 ( Figure 9 ). This interfaces radially with ratchet features 66 on the dose setting element 60. During dispense, as the dose setting element 60 rotates and the button 70 is rotationally coupled to the housing 10, the features 66 interact with the clicker arm 72 to produce an audible click with each dose increment (dose count) delivered.
  • the drive sleeve 40 and dose setting element 60 rotate together, so that no relative motion in the last dose nut 50 occurs.
  • the last dose nut 50 therefore travels axially along the drive sleeve 40 only during dialling (and reset).
  • the user may release the button 70, which will re-engage the drive sleeve 40 spline teeth 41, 151 with the reset plate 150.
  • the mechanism is now returned to the at rest condition.
  • the mechanism also contains a cartridge holder spring 160 which acts on the rear face (rim) of the cartridge 100 to bias it in a distal direction. This aids dose accuracy as it ensures the cartridge 100 is always biased distally, removing the effect of the tolerance on the cartridge 100 length and the possibility of the cartridge 100 moving proximally when a needle is fitted to the device.
  • the cartridge holder spring 160 consists of a wave spring component, but it may equally be any spring means.
  • the user first unscrews the cartridge holder 20, which allows the trigger spring 130 to move the reset plate 150 (and consequently the dose setting element 60) axially in a distal direction ( Figure 12a ).
  • This axial travel is sufficient to disconnect the splines 41, 151 between the reset plate 150 and the drive sleeve 40 and the splines 122, 65 between the clutch plate 120 and the dose setting element 60. It also removes some compression from the trigger spring 130.
  • an engagement is made between spline teeth 14, 62 on the dose setting element 60 and housing 10 to lock the dose setting element 60 rotationally. This ensures that if a dose has been dialled, the drive spring 90 cannot return the dose setting element 60 to its zero position during the reset operation.
  • the spline interface 64, 71 between the dose setting element 60 and button 70 remains engaged, preventing rotation of the button 70 while in the reset condition.
  • the user can then fit a new cartridge 100 into the cartridge holder 20, and the bearing 140 and piston rod 30 be pushed back into the mechanism.
  • a rotation in the piston rod 30 is generated due to the housing 10 thread interface.
  • This piston rod 30 rotation causes the drive sleeve 40 to rotate due to their spline interface, which acts to backwind the last dose nut 50 towards its start position.
  • the cartridge holder 20 contacts the housing 10 and at this point the bearing 140, piston rod 30 and last dose nut 50 have reached a fully reset position. Pure rotation of the cartridge holder 20 to a locked position then acts to move the reset plate 150 (and consequently dose setting element 60) in a proximal direction, reengaging splines with the drive sleeve 40 and clutch plate 120.
  • pressing of the button 70 with the device in the reset condition will cause re-engagement of splines 41, 151 between the drive sleeve 40 and reset plate 150, preventing any further actions to reset the device until the button 70 is released.

Landscapes

  • Health & Medical Sciences (AREA)
  • Vascular Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Claims (15)

  1. Dispositif d'administration de médicament permettant de sélectionner et de distribuer un certain nombre de doses, qu'un utilisateur peut faire varier, d'un produit médicinal, le dispositif comprenant :
    un boîtier (10), un élément de définition de dose (60) apte à tourner par rapport au boîtier (10) lors de la définition d'une dose et de la distribution d'une dose, un organe d'entraînement (40) accouplé à l'organe de définition de dose (60) par le biais d'un embrayage (120), une tige de piston (30) accouplée au boîtier (10) et à l'organe d'entraînement (40), un mécanisme de protection de dernière dose comprenant un élément formant écrou (50) intercalé entre l'organe d'entraînement (40) et l'élément de définition de dose (60), un support de cartouche (20) attaché de manière amovible au boîtier (10), un élément de réarmement (150) et au moins un ressort (130) agissant sur l'élément de réarmement (150), de telle sorte que, si le support de cartouche (20) est détaché du boîtier (10), l'élément de réarmement (150) soit déplacé axialement par rapport au boîtier (10) jusqu'à une position dans laquelle l'organe d'entraînement (40) peut tourner par rapport au boîtier (10), caractérisé en ce que l'élément de réarmement (150) est assujetti axialement à l'élément de définition de dose (60) et en ce que, dans la position de l'élément de réarmement (150) dans laquelle l'organe d'entraînement (40) peut tourner par rapport au boîtier (10), l'élément de définition de dose (60) est assujetti du point de vue de la rotation au boîtier (10).
  2. Dispositif d'administration de médicament selon la revendication 1, dans lequel, si le support de cartouche (20) est attaché au boîtier (10), le support de cartouche (20) déplace l'élément de réarmement (150) et l'élément de définition de dose (60) à l'encontre de la sollicitation du ou des ressorts (130) jusqu'à une position dans laquelle l'élément de définition de dose (60) est apte à tourner par rapport au boîtier (10).
  3. Dispositif d'administration de médicament selon la revendication 1 ou 2, dans lequel l'élément de réarmement (150) est assujetti du point de vue de la rotation au boîtier (10) de manière permanente.
  4. Dispositif d'administration de médicament selon l'une quelconque des revendications précédentes, dans lequel l'organe d'entraînement (40) est déplaçable axialement par rapport au boîtier (10) entre une position de définition de dose, dans laquelle l'organe d'entraînement (40) est assujetti du point de vue de la rotation au boîtier (10) par le biais de l'élément de réarmement (150), et une position de distribution de dose, dans laquelle l'organe d'entraînement (40) est apte à tourner par rapport à l'élément de réarmement (150) et au boîtier (10).
  5. Dispositif d'administration de médicament selon la revendication 4, dans lequel le ou les ressorts (130) sollicitent l'organe d'entraînement (40) vers sa position de définition de dose.
  6. Dispositif d'administration de médicament selon l'une quelconque des revendications précédentes, dans lequel le boîtier (10) comprend une paroi ou plaque (12) faisant saillie vers l'intérieur avec une ouverture centrale et au moins une autre ouverture, le support de cartouche (20) ou l'élément de réarmement (150) comprenant au moins un doigt à étendue axiale s'étendant à travers l'autre ouverture.
  7. Dispositif d'administration de médicament selon la revendication 6, dans lequel la paroi ou plaque (12) faisant saillie vers l'intérieur comprend un filetage intérieur et dans lequel la tige de piston (30) est assujettie du point de vue de la rotation à l'organe d'entraînement (40) et comprend un filetage extérieur (31) coopérant avec le filetage intérieur.
  8. Dispositif d'administration de médicament selon la revendication 6 ou 7, comprenant en outre au moins un ressort de support de cartouche (160) intercalé axialement entre le support de cartouche (20) et la paroi ou plaque (12) faisant saillie vers l'intérieur.
  9. Dispositif d'administration de médicament selon l'une quelconque des revendications précédentes, comprenant en outre un ressort d'entraînement (90), de préférence un ressort de torsion (90), intercalé entre le boîtier (10) et l'élément de définition de dose (60).
  10. Dispositif d'administration de médicament selon l'une quelconque des revendications précédentes, comprenant en outre un élément de mesure (110) intercalé radialement entre le boîtier (10) et l'élément de définition de dose (60), dans lequel l'élément de mesure (110) est déplaçable axialement par rapport au boîtier (10) et en prise par vissage avec l'élément de définition de dose (60) .
  11. Dispositif d'administration de médicament selon la revendication 10, dans lequel le boîtier (10) comprend au moins un orifice (11a, 11b), l'élément de mesure (110) comprend au moins un orifice (111), l'élément de définition de dose (60) comprend des marques sur sa surface extérieure et dans lequel au moins une des marques est visible à travers l'orifice (111) dans l'élément de mesure (110) et l'orifice (11b) dans le boîtier (10) lors de la définition d'une dose et de la distribution d'une dose.
  12. Dispositif d'administration de médicament selon la revendication 10 ou 11, dans lequel l'élément de mesure (110) comprend une butée d'arrêt de rotation de dose minimale et une butée d'arrêt de rotation de dose maximale et l'élément de définition de dose comprend une butée opposée d'arrêt de rotation de dose minimale et une butée opposée d'arrêt de rotation de dose maximale.
  13. Dispositif d'administration de médicament selon l'une quelconque des revendications précédentes, dans lequel l'embrayage (120) entre l'élément de définition de dose (60) et l'organe d'entraînement (40) est un limiteur de couple à friction (42, 121) avec une première couronne de dents d'embrayage (42) sur l'organe d'entraînement (40) et une seconde couronne de dents d'embrayage (121) sur une plaque d'embrayage (120), qui est assujettie du point de vue de la rotation à l'élément de définition de dose (60) lors de la définition d'une dose et de la distribution d'une dose.
  14. Dispositif d'administration de médicament selon la revendication 13, dans lequel le ou les ressorts (130) sollicitent l'organe d'entraînement (40) de sorte qu'il vienne en appui contre la plaque d'embrayage (120), et dans lequel, si le support de cartouche (20) est détaché du boîtier (10), le ou les ressorts (130) sollicitent l'élément de définition de dose (60) vers une position axiale par rapport à la plaque d'embrayage (120) dans laquelle la plaque d'embrayage (120) et l'élément de définition de dose (60) sont désaccouplés du point de vue de la rotation.
  15. Dispositif d'administration de médicament selon l'une quelconque des revendications précédentes, comprenant en outre une cartouche (100) contenant un produit médicinal.
EP15777963.8A 2014-10-09 2015-10-09 Dispositif d'injection de médicament avec mécanisme pour faire reculer la tige de piston en changeant la cartouche Active EP3204075B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14306599 2014-10-09
PCT/EP2015/073443 WO2016055635A1 (fr) 2014-10-09 2015-10-09 Dispositif d'injection de médicament comportant un mécanisme réinitialisable permettant une rétractation de tige de piston lors d'un changement de cartouche de médicament

Publications (2)

Publication Number Publication Date
EP3204075A1 EP3204075A1 (fr) 2017-08-16
EP3204075B1 true EP3204075B1 (fr) 2018-09-26

Family

ID=51790645

Family Applications (1)

Application Number Title Priority Date Filing Date
EP15777963.8A Active EP3204075B1 (fr) 2014-10-09 2015-10-09 Dispositif d'injection de médicament avec mécanisme pour faire reculer la tige de piston en changeant la cartouche

Country Status (7)

Country Link
US (1) US10350360B2 (fr)
EP (1) EP3204075B1 (fr)
JP (1) JP6573666B2 (fr)
CN (1) CN106794307B (fr)
DK (1) DK3204075T3 (fr)
TR (1) TR201819651T4 (fr)
WO (1) WO2016055635A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018078187A1 (fr) * 2016-10-31 2018-05-03 Novo Nordisk A/S Dispositif d'administration de médicament
WO2018076341A1 (fr) * 2016-10-31 2018-05-03 创新精密仪器有限公司 Mécanisme de réinitialisation et dispositif d'administration de médicaments correspondant
US10688247B2 (en) 2017-07-13 2020-06-23 Haselmeier Ag Injection device with flexible dose selection
US11969583B2 (en) 2018-07-17 2024-04-30 Medmix Switzerland Ag Injection device with dose interruption fail safe
GB201906941D0 (en) * 2019-05-16 2019-07-03 Owen Mumford Ltd Injection device
CN110575588B (zh) * 2019-09-29 2024-12-31 无锡鸿羽医疗科技有限公司 一种全自动胰岛素注射笔的储药仓安全保险装置
CN114141087B (zh) * 2021-12-29 2025-04-22 深圳惠迈智能科技有限公司 仿真注射笔

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8809115D0 (en) * 1988-04-18 1988-05-18 Turner R C Syringes
GB0007071D0 (en) * 2000-03-24 2000-05-17 Sams Bernard One-way clutch mechanisms and injector devices
US6899699B2 (en) * 2001-01-05 2005-05-31 Novo Nordisk A/S Automatic injection device with reset feature
DE602005017182D1 (de) 2004-10-21 2009-11-26 Novo Nordisk As Injektionsvorrichtung mit torsionsfeder und drehbarer anzeige
PL208660B1 (pl) * 2005-05-25 2011-05-31 Kappa Medilab Społka Z Ograniczoną Odpowiedzialnością Automatyczny aplikator, zwłaszcza do insuliny
JP2010503431A (ja) * 2006-09-15 2010-02-04 テクファーマ・ライセンシング・アクチェンゲゼルシャフト はね返り防止注射装置
DE102008011886A1 (de) * 2008-02-29 2009-09-24 Tecpharma Licensing Ag Injektionsvorrichtung mit einer Einrichtung zur Verhinderung von Fehlausschüttungen
PT2274030E (pt) 2008-05-02 2012-12-07 Sanofi Aventis Deutschland Dispositivo de administração de medicamento
DE202008011175U1 (de) * 2008-08-18 2010-01-07 Haselmeier Gmbh Injektionsgerät
US8702660B2 (en) 2008-09-09 2014-04-22 Shl Group Ab Medicament delivery device
US8974423B2 (en) * 2009-06-01 2015-03-10 Sanofi-Aventis Deutschland Gmbh Resettable drug delivery device
EP2588163B1 (fr) * 2009-06-05 2025-12-03 SHL Medical AG Dispositif d'administration de médicament
WO2011101349A1 (fr) * 2010-02-17 2011-08-25 Sanofi-Aventis Deutschland Gmbh Dispositif d'injection
EP2579921B1 (fr) * 2010-06-11 2018-05-16 Sanofi-Aventis Deutschland GmbH Mécanisme d'entraînement pour dispositif d'administration de médicaments
PL220720B1 (pl) 2012-02-08 2015-12-31 Copernicus Spółka Z Ograniczoną Odpowiedzialnością Urządzenie wstrzykujące z mechanizmem resetu dawki
EP3639872B1 (fr) 2012-08-31 2023-01-25 Sanofi-Aventis Deutschland GmbH Dispositif d'administration de médicament
EP2829292B1 (fr) * 2013-07-22 2017-11-01 TecPharma Licensing AG Dispositif d'entraînement et de dosage comprenant un élément de limitation pour empêcher le réglage d'une dose plus grande que disponible
CN106535963A (zh) * 2014-07-25 2017-03-22 诺和诺德股份有限公司 用于医疗装置的螺母组件

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None *

Also Published As

Publication number Publication date
US10350360B2 (en) 2019-07-16
TR201819651T4 (tr) 2019-01-21
DK3204075T3 (en) 2019-01-21
JP2017530797A (ja) 2017-10-19
CN106794307A (zh) 2017-05-31
CN106794307B (zh) 2020-09-25
JP6573666B2 (ja) 2019-09-11
EP3204075A1 (fr) 2017-08-16
US20170304551A1 (en) 2017-10-26
WO2016055635A1 (fr) 2016-04-14

Similar Documents

Publication Publication Date Title
EP3204087B1 (fr) Dispositif d'administration de médicament ré-enclenchable
EP3204077B1 (fr) Dispositif d'injection de médicament avec mécanisme pour faire reculer la tige de piston en changeant la cartouche
EP3204085B1 (fr) Boîtier et dispositif d'administration de médicament le comprenant
EP3204075B1 (fr) Dispositif d'injection de médicament avec mécanisme pour faire reculer la tige de piston en changeant la cartouche
EP3204086B1 (fr) Boîtier et dispositif d'administration de médicament associé
EP3204084B1 (fr) Manchon de guidage, dispositif d'administration de médicament et procédé pour assembler un tel dispositif
WO2016055619A1 (fr) Boîtier et dispositif d'administration de médicament le comprenant, et procédé de production de boîtier
EP3223887B1 (fr) Affichage et dispositif d'administration de médicament associé
EP3204090B1 (fr) Dispositif d'administration de médicament ré-enclenchable
EP3204078B1 (fr) Mécanisme d'entraînement et dispositif d'administration de médicament associé
EP3204073B1 (fr) Procédé d'assemblage d'un ressort d'entraînement et dispositif d'administration de médicament doté d'un ressort
HK1239581A1 (en) Drug injection device with resettable mechanism allowing piston rod retraction upon drug cartridge change
HK1239581B (en) Drug injection device with resettable mechanism allowing piston rod retraction upon drug cartridge change
HK1239583B (en) Drug injection device with resettable mechanism allowing piston rod retraction upon drug cartridge change
HK1239583A1 (en) Drug injection device with resettable mechanism allowing piston rod retraction upon drug cartridge change
HK1239577B (en) Resettable drug delivery device
HK1239588B (en) Housing and drug delivery device herewith
HK1239588A1 (en) Housing and drug delivery device herewith

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20170427

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Ref document number: 602015017164

Country of ref document: DE

Free format text: PREVIOUS MAIN CLASS: A61M0005200000

Ipc: A61M0005310000

RIC1 Information provided on ipc code assigned before grant

Ipc: A61M 5/20 20060101ALI20180214BHEP

Ipc: A61M 5/31 20060101AFI20180214BHEP

Ipc: A61M 5/315 20060101ALI20180214BHEP

Ipc: A61M 5/24 20060101ALI20180214BHEP

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1239581

Country of ref document: HK

INTG Intention to grant announced

Effective date: 20180430

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1045267

Country of ref document: AT

Kind code of ref document: T

Effective date: 20181015

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602015017164

Country of ref document: DE

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20190116

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20180926

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181226

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180926

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180926

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180926

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180926

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181227

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181226

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180926

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180926

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180926

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1045267

Country of ref document: AT

Kind code of ref document: T

Effective date: 20180926

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180926

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180926

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180926

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180926

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180926

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180926

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180926

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190126

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180926

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180926

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190126

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180926

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20181031

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602015017164

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181009

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180926

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181031

26N No opposition filed

Effective date: 20190627

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181009

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180926

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181009

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180926

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20151009

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180926

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20191009

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20240904

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DK

Payment date: 20241011

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20241101

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20250904

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20250908

Year of fee payment: 11

REG Reference to a national code

Ref country code: CH

Ref legal event code: U11

Free format text: ST27 STATUS EVENT CODE: U-0-0-U10-U11 (AS PROVIDED BY THE NATIONAL OFFICE)

Effective date: 20251101